SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-296686
Filing Date
2022-12-01
Accepted
2022-12-01 17:22:59
Documents
14
Period of Report
2022-11-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d358556d8k.htm   iXBRL 8-K 31674
2 EX-1.1 d358556dex11.htm EX-1.1 170432
3 EX-5.1 d358556dex51.htm EX-5.1 6552
  Complete submission text file 0001193125-22-296686.txt   383153

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ntla-20221130.xsd EX-101.SCH 2847
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20221130_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20221130_pre.xml EX-101.PRE 11259
8 EXTRACTED XBRL INSTANCE DOCUMENT d358556d8k_htm.xml XML 3344
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 221439688
SIC: 2835 In Vitro & In Vivo Diagnostic Substances